Correlation of prothrombin time and activated partial thromboplastin time with serum immunoglobulin and M-band in newly diagnosed multiple myeloma patients

Javid R. Shah; Nusrat Bashir; Lateef A. Wani; Sheikh Bilal; Fahim Manzoor; Rakesh Koul; Mohammad Yousuf

doi:10.18203/2320-6012.ijrms20233019

Authors

Javid R. Shah Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India
Nusrat Bashir Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India
Lateef A. Wani Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India
Sheikh Bilal Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India
Fahim Manzoor Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India
Rakesh Koul Department of General Medicine, Government Medical College, Srinagar, Jammu and Kashmir, India
Mohammad Yousuf Department of Pathology, Government Medical College, Srinagar, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20233019

Keywords:

APTT, PT, M-band, Myeloma

Abstract

Background: Multiple myeloma is the second most frequent malignancy which constitute 13% of hematologic cancers. Thrombotic and hemorrhagic complications have been frequently observed in multiple myeloma patients.

Methods: The study was conducted in the department of pathology, Government medical college Srinagar. A total of fifty (50) patients were recruited for the study. The patients were advised coagulation profile and complete myeloma profile.

Results: Our findings indicate that prolonged PT is associated with high serum IgG levels. A mild to moderate correlation was seen with kappa-free light chains and an inverse correlation was seen between PT and lmbda-free light chains.

Conclusions: Screening of multiple myeloma for hemostatic abnormalities at the diagnosis should improve prognosis in such cases.

Metrics

Metrics Loading ...

References

Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565-75.

Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225-36.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, eds. WHO classification of tumors of hematopoietic and lymphoid tissues. Revised 4th edn. World Health Organization; 2017.

Firth J. Medical Masterclass contributors, Haematology: multiple myeloma. Clin Med. 2019;19(1):58-60.

Parker CH, Henry S, Liu LW. Efficacy of biofeedback therapy in clinical practice for the management of chronic constipation and fecal incontinence. J Can Assoc Gastroenterol. 2019;2(3):126-31.

Li FA, Zhang QK, Wei XF, Feng YF. Coagulation indexes and their prognostic significance in patients with Multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(3):791-6.

Fotiou, Gavriatopoulou M, Stathopoulos IN, Migkou M, Dimopoulos MA, Terpos E. Updates on thrombotic events associated with multiple myeloma. Exp Rev Hematol. 2019;12(5):35565.

Baccouche H, Hadhri MW, Aissi W. The hypercoagulable state in multiple myeloma: the contribution of thrombin generation test. Int J Lab Hematol. 2019;41(5):684-90.

Nielsen T, Kristensen SR, Gregersen H, Teodorescu EM, Pedersen S. Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Thromb Res. 2021;202:108-18.

Inano S, Oku Y, Aiba A. Acquired hypofibrinogenemia in a patient with multiple myeloma. Int J Hematol. 2021;114(3):395-400.

Perkins HA, MacKenzie MR, Fudenberg HH. Hemostatic defects in dysproteinemias. Blood. 1970;35(5):695-707.

Glaspy JA. Haemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am. 1992;6:1301-14.

Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol. 1997;97(1):219-26.

Carr ME Jr, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med. 1996;128(1):83-8.

Pandey S, Post SR, Alapat DV, Smock KJ, Post GR. Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia. Int J Lab Hematol 2013;35:421-7.